SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending as the community discusses potential catalysts and its broader ecosystem. Conversations highlight the emergence of new meme coins built on Solana, like $SOLYCAT and $CAW, while others focus on staking opportunities. There is also bullish sentiment around its long-term potential and increasing institutional interest as Fidelity now offers Solana.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

The meme coin "crow with knife" ($CAW) is gaining attention, with community members highlighting its deflationary mechanism and presence across multiple chains like Solana, BSC, CRO, and ETH.  Enthusiasts are also excited about potential staking opportunities and partnerships. Community buzz is focused on its organic growth and strong "cult" following.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI is trending as community members express strong conviction and highlight its price stability within the Solana ecosystem. Discussions also focus on WAGMI's potential for significant revaluation, drawing comparisons to other successful meme coins like DOGE and SHIB. The community emphasizes WAGMI's organic growth and potential for long-term gains, with some anticipating a major breakout.

The SolyCat is a symbol of energy and mystery. Shining like the sun and agile as a feline.  Solycat is here to take over Solana! Inspired by Shiba Inu’s legendary rise on Ethereum, Solycat is the ultimate meme coin designed for Solana’s fast and scalable blockchain.  Our mission is simple: become the top cat of Solana. With bold branding, a vibrant community, and unstoppable momentum, Solycat is ready to dominate. This isn’t just another token—it’s a movement powered by fun, creativity, and the spirit of decentralization.  Join the pride and let’s make history, one paw at a time!

Solycat

Solycat ($SOLYCAT) is trending as a new Solana-based meme token, generating buzz around its recent launch and availability on Phantom Wallet. The community is drawn to its potential for high gains, with many emphasizing its momentum within the Solana ecosystem alongside established tokens. Conversations highlight its strong chart and potential breakout.

USDC is a fully collateralized US dollar stablecoin. USDC is the bridge between dollars and trading on cryptocurrency exchanges. The technology behind CENTRE makes it possible to exchange value between people, businesses and financial institutions just like email between mail services and texts between SMS providers. We believe by removing artificial economic borders, we can create a more inclusive global economy.

USD Coin

USD Coin is trending as discussions swirl around stablecoin regulation and its potential role in the evolving financial landscape. Community members are weighing in on its stability, integration with various platforms like Solana, and comparisons to other stablecoins like USDT.  Additionally, its adoption in decentralized finance (DeFi) and real-world applications, like cross-border payments and tokenized assets, are being closely monitored.

An AI x Metaverse Protocol that is building the future of virtual interactions.

Virtual Protocol

Virtual Protocol is trending as the community discusses its recent price action and potential. Some traders are pointing to listing on Robinhood as a catalyst, while others debate whether it's a pump and dump, but many bulls see strong potential due to the project's focus on AI and development of AI agents. Discussion includes the ecosystem utility and agents like G.A.M.E, which are gaining traction.

WISeKey International Holding Ltd. is a cybersecurity company, which engages in offering digital security technology solutions. The firm operates through the Internet of Things (IoT), and Managed Public Key Infrastructure (mPKI) segments. The IoT segment refers to the design, manufacturing, sales and distribution of microprocessors operations. The mPKI segment includes all operations relating to the provision of secured access keys, authentication, signing software, certificates and digital security applications. The company was founded by Joao Carlos Creus Moreira and Philippe Doubre in 1999 and is headquartered in Zug, Switzerland.

WISeKey International Holding Ltd - ADR

WISeKey is trending as investors discuss its potential upside in the post-quantum computing era, particularly in securing satellite constellations. The community is highlighting the company's subsidiaries, including SEALCOIN and WISeSat, and comparing its market cap to its parent company, LAES.  Some investors believe WKEY's current valuation doesn't reflect the value of its assets and potential growth in the quantum security market.

Cronos is an institutional-grade, high-performance, EVM-compatible Layer-1 blockchain built on the Cosmos SDK and integrated with the Inter-Blockchain Communication (IBC) protocol, designed as the backbone for open, compliant, and AI-accessible tokenized markets. It supports up to 60,000 transactions per second (TPS), 500ms block times, instant finality, and sub-$0.01 fees via Proof of Authority consensus.

Crypto.com Coin

Crypto.com Coin is trending as the community discusses its potential, partnerships, and possible ETF. A segment of the community is focused on the token's multi-chain presence through projects like $CAW. Others express frustration with price action, debating whether to buy and stake or take profits.

Infinite Money Glitch ($IMG) is revolutionizing DeFi on Solana by leveraging the Token2022 program's advanced tax extension capabilities to create a truly innovative reward system for token holders.  At its core, $IMG implements a seamless 5% tax on all transactions - whether buying, selling, or transferring tokens. This tax is automatically collected and distributed to holders in SOL, creating a sustainable passive income stream for the community. 4.5% of the tax gets sent to holders, while .5% gets sent to an Infrastructure wallet to help with development, marketing and general infrastructure.  What sets $IMG apart is its implementation of Solana's Token2022 program, enabling automated and efficient reward distribution without relying on external smart contracts.

Infinite Money Glitch

IMG is trending as the community rallies around its unique rewards system, which distributes $SOL to holders, and its participation in the Solana Cypherpunk Hackathon. Community members highlight the project's transparent and automated $SOL distribution as a key differentiator in the DeFi space. The community emphasizes its conviction in the project's long-term vision of a sustainable, community-driven ecosystem on the Solana blockchain.

Pump.fun

$PUMP is trending as traders discuss its strong community and potential within the Solana ecosystem, with many mentioning $WAGMI and highlighting the token's resilience. Community members are emphasizing holding for the long term and believe the project is coded for success. The conversation includes discussion of potential catalysts and continued building within the $SOL ecosystem.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of...

Halper Sadeh LLC Encourages Acadia Pharmaceuticals Inc. Shareholders to Contact the Firm to Discuss Their Rights

Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) breached their fiduciary duties to shareholders...

Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions

Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions PR Newswire VANCOUVER, Oct. 21, 2025 Equity...

Acadia Pharmaceuticals to Announce Third Quarter 2025 Financial Results on November 5, 2025

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will report third quarter 2025 financial results on Wednesday, November 5, 2025, after the close of the U.S. financial markets...

QGEN vs. ACAD: Which Stock Is the Better Value Option?

Can Auvelity Drive Axsome's Growth Through the Rest of 2025?

AXSM's Auvelity drives 82% sales growth in the first half of 2025, with label expansion studies and other marketed products bolstering its CNS drug portfolio.

ACAD Stock Down 10% Following Phase III Hyperphagia Study Failure

Acadia Pharmaceuticals stock tumbles 10% after its phase III hyperphagia study failure, but growth remains driven by Nuplazid, Daybue and a robust pipeline.

Acadia Pharmaceuticals Inc. (ACAD) announced on Tuesday that its late-stage intranasal Carbetocin trial in Prader-Willi syndrome (PWS) patients did not achieve a statistically significant improvement in hyperphagia.The <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://acadia.com/en-us/media/news-releases/acadia-pharmaceuticals-announces-phase-3-compass-pws-trial">study</a> enrolled 175 children and adults aged five to 30 years with PWS, a rare genetic disorder characterized by an insatiable hunger or hyperphagia and a constant need for food, leading to obesity. However, intranasal Carbetocin did not demonstrate a statistically significant improvement over placebo to week 12 on the Hyperphagia Questionnaire for Clinical Trials, the company said.The firm noted that the safety and tolerability of intranasal Carbetocin were consistent with those observed in previous clinical trials, with a low rate of adverse events.Shares of the company tumbled 11% in the pre-market session. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/ACAD">ACAD stock</a> stayed within the ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.Acadia’s Head of Research and Development, Elizabeth HZ Thompson, said that the company is “disappointed” by these findings. “We are committed to sharing a summary of the data in the future to ensure learning for the PWS community; however, given these results, we do not intend to investigate intranasal carbetocin any further,” Thompson added.CEO Catherine Owen Adams highlighted that the firm’s approved products are projected to generate over $1 billion in net sales in 2025 despite the disappointment with the trial. The company’s drugs for the treatment of Rett syndrome and for treating hallucinations and delusions associated with Parkinson’s disease psychosis are approved by the U.S. Food and Drug Administration.“Looking ahead, we anticipate seven Phase 2 or 3 study starts through 2026 and four data readouts by the end of 2027,” the CEO added.ACAD stock is up 29% this year and approximately 49% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-is-mp-materials-stock-rising-today/chD1R9FR330">Why Is MP Materials Stock Rising Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, an Acadia Pharmaceuticals company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Acadia Pharmaceuticals’ Investigational Drug For Rare Genetic Disorder Fails In Late-Stage Study 

The company noted that the safety and tolerability of intranasal Carbetocin were consistent with those observed in previous clinical trials.

Equity

The company noted that the safety and tolerability of intranasal Carbetocin were consistent with those observed in previous clinical trials.


Axsome Shares Up 20% in a Month: How Should You Play the Stock?

AXSM shares rise 20.2% in a month, powered by booming Auvelity sales and a growing CNS drug pipeline.

ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

Acadia Pharmaceuticals Inc

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	$0.14	--	--	N/A
Q2 '25	$0.14	$0.16	15.88%	BEAT
Q1 '25	$0.09	$0.11	26.93%	BEAT
Q4 '24	$0.22	$0.86	298.68%	BEAT
Q3 '24	$0.14	$0.20	44.84%	BEAT

ACAD
Acadia Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest ACAD News

ACADAcadia Pharmaceuticals Inc